Plasma Protein - Webinars

Learn how the free light chain (FLC) assay has revolutionized the care of diseases caused by the systemic proteotoxic effect exerted by light chains, such as AL amyloidosis, light chain deposition disease, and monoclonal gammopathies of renal significance.

Update Multiple Sclerosis

In the last decade, Cystatin C assay has become more reliable, harmonized and inexpensive.

Learn why Cystatin C is currently the best endogenous marker of GFR and why Beta trace protein may be better for pregnancy and neonates.

Watch and learn how C-reactive protein is an established marker for diagnosing and monitoring infection, inflammation, and tissue injury.

Nontraditional factors are involved in CKD-related heart disease. Learn how to interpret cardiac biomarkers in CKD.

Watch late-breaking news on inflammation and the impact of SAA on cardiovascular risk in the LURIC study.

Join our complimentary webcast to learn why IgG4 immunostaining is essential for the pathological diagnosis of IgG4-related disease.

Residual Kidney Function (RKF) is an important contributor to dialysis clearance and a strong predictor of survival in dialysis patients. Learn more.

BTP - a robust and reliable marker for estimation of residual kidney function

Markers of Renal Diseases

Residual renal function in dialysis patients: Why this is important to know

Learn more about the need for established FLC reference ranges.

Learn about one of the few studies available that provides a comparative analysis of the performance of the new Siemens FLC assay and an existing method.

Understand the capabilities of the Siemens FLC method for the determination of kappa free light chains (FLC) in cerebrospinal fluid as a possible diagnostic marker for multiple sclerosis.